Korsana Biosciences, Inc. (KRSA) AI Stock Analysis

Korsana Biosciences, Inc. develops therapeutic antibodies for the treatment of neurodegenerative diseases. The company developed Therapeutic Targeting (THETA), a blood-brain barrier-penetrant shuttle platform engineered to enhance central nervous system exposure of investigational therapies and enable delivery of large therapeutic molecules across the blood-brain barrier. Korsana is advancing a pipeline of THETA-enabled therapeutics with an initial focus on neurodegenerative disorders. Its lead candidate is KRSA-028, an anti-amyloid beta antibody for Alzheimer's disease designed to enhance brain uptake while reducing effects on reticulocytes. The company was incorporated in 2024 and is based in Waltham, Massachusetts.

Korsana's annual revenue has fluctuated historically, moving from $2.3M in FY2020 to $3.3M in FY2021, before dropping to $297,000 in FY2022. Revenue reached $2.0M in FY2024 and grew 3.7% to $2.1M in FY2025, but 5-year revenue CAGR from FY2019 to FY2025 was -14.4%. Operating margins improved from -3539.4% in FY2020 to -239.8% in FY2025. Annual net losses decreased from -$77.8M in FY2020 to -$3.5M in FY2025, with EPS finishing at -$6.96. For the trailing twelve months ended June 30, 2026, revenue stood at $0 with an operating margin of 0.0% and an EPS of -$7.07.

As of June 30, 2026, Korsana held $1.4M in cash and short-term investments, with total assets of $6.9M and shareholders' equity of $5.1M. The company had a current ratio of 0.82. In FY2025, operating cash flow was -$3.3M, and free cash flow was -$3.3M. Research and development expenses totaled $959,000 in FY2025. Cash use included $130,000 spent on share buybacks in FY2025, while the company's share count expanded by 106.3% over a 5-year period.

Korsana carries a market capitalization of $1.47B and an enterprise value of $1.35B. Trailing and forward price-to-earnings ratios are not applicable due to negative earnings, compared to the median of its US-listed Healthcare peers of 24.6x trailing and 17.3x forward. The peer group median price-to-sales multiple is 4.1x, and EV to EBITDA is 12.0x. Over the past year, Korsana's stock rose 105.6%, outperforming the S&P 500 return of 16.8%. However, over a 5-year span, the stock fell 91.4% while the S&P 500 rose 83.0%.

Wall Street coverage includes 5 Strong Buy ratings, with zero Buy, Hold, Sell, or Strong Sell ratings. The mean analyst price target is $44.00, representing a 35.9% upside compared to the last close of $32.38 on October 16, 2026. For the fiscal year ending December 31, 2026, analysts estimate an EPS of -$1.70 on $0 in revenue. For the following fiscal year, 1 analyst estimates an EPS of -$3.56 and revenue of $0. The company's next earnings date is scheduled for November 11, 2026.

This page is an AI-written research summary of Korsana Biosciences, Inc. (KRSA). The text was generated on October 30, 2026 from Quotelinks data as of October 16, 2026 (company profile, annual results, latest balance sheet, valuation, price performance and analyst estimates). An automatic check rejects any draft that contains a figure not found in that data. It is not investment advice; verify figures on the linked tabs before making decisions.

Related: KRSA income statement, KRSA balance sheet, KRSA key metrics, KRSA analyst forecast, KRSA chart. See the KRSA stock overview for the latest quote and news.